| 翻訳と辞書 |
ibrutinib
Ibrutinib (USAN,〔(Statement on a Nonproprietary Name Adopted by the USAN Council )〕 also known as PCI-32765 and marketed under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It was approved by the US Food and Drug Administration (FDA) in November 2013 for the treatment of mantle cell lymphoma〔(【引用サイトリンク】 FDA approves Imbruvica for rare blood cancer )〕 and in February 2014 for the treatment of chronic lymphocytic leukemia.〔 It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase (BTK).〔(【引用サイトリンク】 work = Celera: Personalizing Disease Management: Press Releases )〕 Ibrutinib is currently under development by Pharmacyclics, Inc and Johnson & Johnson's Janssen Pharmaceutical division for additional B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma.〔(【引用サイトリンク】 Clinical trials involve ibrutinib )〕 In January 2015, ibrutinib was approved by the FDA for treatment of Waldenström's macroglobulinemia, a form of non-Hogkins lymphoma.
==Medical uses==
It is FDA-approved as a treatment for mantle cell lymphoma〔 and chronic lymphocytic leukemia.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「ibrutinib」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|